Enhancement of the cellular immune response

Details Enhancement of the cellular immune response Enhancement of the cellular immune response

C - Chemistry, Metallurgy

12

N

167/104, 167/114

C12N 5/08 (2006.01) A61K 35/14 (2006.01) A61K 35/28 (2006.01) A61K 39/00 (2006.01) C12N 5/06 (2006.01)

Patent

CA 1339494

DTH-Effector T-cells expressing the CD5 and not the CD8 phenotype are primed with an antigen containing a specific [tumor-associated] tumour-associated carbohydrate determinant and are used to enhance the cellular immune response. [Tumors] Tumours have been inhibited by DTH-Effector cells expressing the CD5 and not the CD8 phenotype cells primed with such antigen containing a [tumor-associated] tumour-associated specific carbohydrate determinant, e.g., with epiglycanin and with synthetic T and Tn antigens. Either the DTH-Effector cells expressing the CD5 and not the CD8 phenotype, or [those specific tumor-associated] tumour-associated carbohydrate antigens [directly], may be used for [tumor] tumour prophylaxis and therapy, and/or for enhancing cellular immunity in a mammal.

617073

Affiliated with

Also associated with

Rating

Enhancement of the cellular immune response does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Enhancement of the cellular immune response, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enhancement of the cellular immune response will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1313437